Firefly Neuroscience (NASDAQ:AIFF) Trading Up 5.9% – Still a Buy?

Posted by Brenda Bartman on Aug 2nd, 2026

Firefly Neuroscience, Inc. (NASDAQ:AIFF – Get Free Report) shares were up 5.9% during mid-day trading on Friday . The stock traded as high as $1.08 and last traded at $1.07. Approximately 66,267 shares were traded during mid-day trading, a decline of 28% from the average session volume of 91,405 shares. The stock had previously closed at $1.01.

Analyst Upgrades and Downgrades

AIFF has been the subject of a number of analyst reports. Weiss Ratings upgraded Firefly Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, May 19th. Wall Street Zen raised shares of Firefly Neuroscience from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

View Our Latest Stock Analysis on AIFF

Firefly Neuroscience Stock Performance

The stock has a 50 day moving average price of $1.36 and a 200 day moving average price of $1.45. The company has a market capitalization of $16.70 million, a P/E ratio of -1.70 and a beta of 0.55.

Firefly Neuroscience (NASDAQ:AIFF – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.13) EPS for the quarter. Firefly Neuroscience had a negative net margin of 565.40% and a negative return on equity of 94.68%. The business had revenue of $0.48 million for the quarter.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new position in shares of Firefly Neuroscience in the 4th quarter worth $53,000. Geode Capital Management LLC lifted its holdings in shares of Firefly Neuroscience by 92.9% during the 2nd quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock worth $341,000 after acquiring an additional 58,067 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Firefly Neuroscience by 393.3% during the 3rd quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock worth $1,464,000 after acquiring an additional 401,085 shares during the last quarter. Hedge funds and other institutional investors own 4.96% of the company’s stock.

About Firefly Neuroscience

(Get Free Report)

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.